Sign In
Buy ALKS
$42.76
+1.44 (+3.48%)
At Close: Jun 03, 2026
LabCorp (LH) Partners HealthVerity to Grow in Drug Development
01:47pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
According to LabCorp (LH), this partnership is expected to broaden its comprehensive, end-to-end drug development and clinical trial programs.
Acer Therapeutics (ACER) Gets CRL for Urea Cycle Disorders Drug
01:43pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
Acer Therapeutics' (ACER) new drug application for ACER-001 to treat urea cycle disorders faces rejection from the FDA. Share price falls 21% following the announcement.
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
01:40pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
Here is how Aclaris Therapeutics (ACRS) and Alkermes (ALKS) have performed compared to their sector so far this year.
Celldex (CLDX) Initiates Phase II Chronic Skin Disorder Study
01:24pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
Celldex (CLDX) initiates dosing in a mid-stage study designed to evaluate its antibody candidate, barzolvolimab, for treating patients with chronic spontaneous urticaria.
J&J's (JNJ) Stock Outperforms Industry YTD: Here's Why
01:23pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
J&J's (JNJ) Pharma unit is performing above market levels. Sales in the Consumer unit are being hurt by external supply constraints. J&J focuses on growing the MedTech segment through new products.
Here's Why You Should Retain National Vision (EYE) For Now
04:14pm, Tuesday, 21'st Jun 2022 Zacks Investment Research
Investors are optimistic about National Vision's (EYE) better-than-expected earnings and new store growth.
4 Biotech Stocks With Bright Prospects to Buy Amid Recovery
01:33pm, Friday, 10'th Jun 2022
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMC
Why Is Alkermes (ALKS) Down 1.4% Since Last Earnings Report?
01:34pm, Friday, 27'th May 2022
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)
03:16am, Wednesday, 25'th May 2022
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication
12:03pm, Monday, 23'rd May 2022
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
Has Alkermes (ALKS) Outpaced Other Medical Stocks This Year?
11:17am, Thursday, 19'th May 2022
Here is how Alkermes (ALKS) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
5 Top Stocks Likely to Beat Earnings Estimates
09:02am, Monday, 02'nd May 2022
These top-ranked stocks (ALKS, DRVN, TSLA, CIB, TFII) are likely to beat on bottom line in their next releases.
Alkermes' (ALKS) CEO Richard Pops on Q1 2022 Results - Earnings Call Transcript
12:54pm, Wednesday, 27'th Apr 2022
Alkermes plc (NASDAQ:ALKS ) Q1 2022 Earnings Conference Call April 27, 2022 8:00 AM ET Company Participants Sandra Coombs - SVP, IR & Corporate Affairs Iain Brown - CFO Todd Nichols - CCO Richard Pops
Why Alkermes Stock Is Jumping Today
12:37pm, Wednesday, 27'th Apr 2022
The drugmaker beat Wall Street's expectations with its Q1 results.
Alkermes (ALKS) Tops Q1 Earnings and Revenue Estimates
10:49am, Wednesday, 27'th Apr 2022
Alkermes (ALKS) delivered earnings and revenue surprises of 1,100% and 6.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
